The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Response to systemic anti-cancer therapy in uncommon EGFR mutations
Hazel O’Sullivan, MBBS, The Royal Marsden NHS Foundation Trust, London, UK, provides an overview of a retrospective analysis of patients with uncommon EGFR mutations treated with systemic anti-cancer therapy. The study revealed patients who were treated with a first-line tyrosine kinase inhibitor (TKI) achieved a response rate of over 40%. The response rate was higher in patients with a compound EGFR mutation. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
